In this episode of the JGO Podcast, we delve into two Editor's Choice articles focused on endometrial cancer. First, we discuss the outcomes of the East Asia subgroup in the KEYNOTE-775 trial, exploring the efficacy and safety of lenvatinib plus pembrolizumab. Then, we introduce a study that analyzed the prognostic significance of immune subtypes in copy-number high endometrial cancer, highlighting potential pathways for personalized treatment strategies.

Article #1: Analysis of East Asia subgroup in Study 309/KEYNOTE-775: lenvatinib plus pembrolizumab versus treatment of physician’s choice chemotherapy in patients with previously treated advanced or recurrent endometrial cancer (https://doi.org/10.3802/jgo.2024.35.e40)

Article #2: Identification of the prognostic immune subtype in copy-number high endometrial cancer (https://doi.org/10.3802/jgo.2024.35.e8)